Objective To explore tumor control in triple-negative breast cancer(TNBC)through low-dose chemotherapy and anti-PD-L1 combination therapy.Methods 4T1 tumor-bearing mice were given either chemotherapy alone or combined with anti-PD-L1.The tumor growth and body weight of these mice were tracked,with immune profiles in the tumor microenvironment(TME)evaluated by flow cytometry.Results After single or combination use of carboplatin,cisplatin and paclitaxel in clinical dosage with or without anti-PD-L1,the body weight of 4T1-tumor bearing mice decreased rapidly and these mice were prone to death.Low-dose carboplatin had no effect on tumor control.Low-dose cisplatin and paclitaxel alone can delay the growth of 4T1,while low-dose cisplatin with anti-PD-L1 could enhance tumor control and increase the number and effector function of tumor-specific CD8+T cells.Conclusion Low-dose cisplatin with anti-PD-L1 presents a promising approach for TNBC control,which is attributed to the increase of tumor-specific CD8+T cells and enhanced effector function.

Objective To explore tumor control in triple-negative breast cancer(TNBC)through low-dose chemotherapy and anti-PD-L1 combination therapy.Methods 4T1 tumor-bearing mice were given either chemotherapy alone or combined with anti-PD-L1.The tumor growth and body weight of these mice were tracked,with immune profiles in the tumor microenvironment(TME)evaluated by flow cytometry.Results After single or combination use of carboplatin,cisplatin and paclitaxel in clinical dosage with or without anti-PD-L1,the body weight of 4T1-tumor bearing mice decreased rapidly and these mice were prone to death.Low-dose carboplatin had no effect on tumor control.Low-dose cisplatin and paclitaxel alone can delay the growth of 4T1,while low-dose cisplatin with anti-PD-L1 could enhance tumor control and increase the number and effector function of tumor-specific CD8+T cells.Conclusion Low-dose cisplatin with anti-PD-L1 presents a promising approach for TNBC control,which is attributed to the increase of tumor-specific CD8+T cells and enhanced effector function.